HER2 positive gastric cancer – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 24 Jun 2026 04:15:20 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png HER2 positive gastric cancer – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study Comparing Rilvegostomig with Fluoropyrimidine and Trastuzumab Deruxtecan to Standard Treatment for Patients with HER2-positive Gastric Cancer https://clinicaltrials.eu/trial/study-comparing-rilvegostomig-with-fluoropyrimidine-and-trastuzumab-deruxtecan-to-standard-treatment-for-patients-with-her2-positive-gastric-cancer/ Wed, 29 Apr 2026 15:05:03 +0000 https://clinicaltrials.eu/trial/study-comparing-rilvegostomig-with-fluoropyrimidine-and-trastuzumab-deruxtecan-to-standard-treatment-for-patients-with-her2-positive-gastric-cancer/ This clinical trial is focused on studying a type of stomach cancer known as HER2-positive gastric cancer. This cancer can also affect the area where the stomach meets the esophagus, called the gastroesophageal junction. The study aims to compare two different treatment approaches for patients with this type of cancer. One group of patients will receive a combination of medications including rilvegostomig, fluoropyrimidine, and trastuzumab deruxtecan. The other group will receive a standard treatment that includes trastuzumab, chemotherapy, and pembrolizumab.

The purpose of the study is to evaluate how effective the new combination of medications is compared to the standard treatment. The study will involve patients receiving these treatments and being monitored over time to see how their cancer responds. The researchers will look at how long patients live without their cancer getting worse and their overall survival time. The study will also monitor any side effects that patients may experience during the treatment.

Participants in the study will receive their treatments through infusions, which means the medication is given directly into a vein. Some medications, like capecitabine, may be taken orally as a tablet. The study will continue for several years to gather enough information to determine the effectiveness and safety of the treatments. This research is important for finding better ways to treat HER2-positive gastric cancer and improve outcomes for patients with this condition.

]]> Study of Trastuzumab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer https://clinicaltrials.eu/trial/study-of-trastuzumab-deruxtecan-and-drug-combination-for-patients-with-advanced-or-metastatic-her2-positive-gastric-or-gastroesophageal-junction-cancer/ Wed, 29 Apr 2026 15:04:42 +0000 https://clinicaltrials.eu/trial/study-of-trastuzumab-deruxtecan-and-drug-combination-for-patients-with-advanced-or-metastatic-her2-positive-gastric-or-gastroesophageal-junction-cancer/ This clinical trial is focused on studying treatments for HER2-positive gastric or gastroesophageal junction cancer, which is a type of cancer that affects the stomach and the area where the stomach meets the esophagus. The study will explore the effectiveness of a new treatment combination involving Trastuzumab Deruxtecan (also known as Enhertu®) along with chemotherapy, with or without the addition of Pembrolizumab. The trial will compare this new combination to the current standard treatment, which includes chemotherapy and Trastuzumab, with or without Pembrolizumab.

The purpose of the study is to determine how well these treatments work in patients who have not received prior treatment for their advanced cancer. Participants will receive their treatment through an intravenous injection, which means the medication is given directly into a vein. The study will last for a period of up to 60 weeks, during which participants will be monitored regularly to assess the progress of their cancer and any side effects they may experience.

Throughout the study, participants will undergo various assessments, including imaging tests like MRI or CT scans, to evaluate the size and spread of the cancer. The trial aims to provide valuable information on the potential benefits of the new treatment combination, which could lead to improved outcomes for patients with this type of cancer. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.

]]> Study on the Safety and Effectiveness of Trastuzumab Deruxtecan with Drug Combination for Patients with HER2+ Resectable Esophagogastric Cancer https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-trastuzumab-deruxtecan-with-drug-combination-for-patients-with-her2-resectable-esophagogastric-cancer/ Wed, 29 Apr 2026 15:03:57 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-trastuzumab-deruxtecan-with-drug-combination-for-patients-with-her2-resectable-esophagogastric-cancer/ This clinical trial is focused on studying a type of cancer called HER2-positive esophagogastric adenocarcinoma, which affects the esophagus and stomach. The study will explore the use of a treatment called trastuzumab deruxtecan, also known by its code name DS-8201a. This treatment will be combined with other medications, including fluorouracil, calcium folinate pentahydrate, and oxaliplatin. These medications are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein.

The purpose of the study is to evaluate the safety and effectiveness of these combination therapies when given before surgery to patients with this type of cancer. The study will involve several phases, where participants will receive the treatment and be monitored for any side effects or changes in their condition. The goal is to determine if this combination of treatments can be safely administered and if it helps in reducing the cancer before surgery.

Participants in the study will receive either the combination of trastuzumab deruxtecan and other medications or a placebo. The study will track how well patients tolerate the treatment and any side effects they experience. The results will help researchers understand if this treatment approach is a viable option for patients with HER2-positive esophagogastric adenocarcinoma.

]]> Study on Long-Term Safety of Trastuzumab Deruxtecan for Patients with Advanced HER2-Positive or HER2-Mutated Solid Tumors https://clinicaltrials.eu/trial/study-on-long-term-safety-of-trastuzumab-deruxtecan-for-patients-with-advanced-her2-positive-or-her2-mutated-solid-tumors/ Wed, 29 Apr 2026 14:56:46 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-of-trastuzumab-deruxtecan-for-patients-with-advanced-her2-positive-or-her2-mutated-solid-tumors/ This clinical trial is focused on studying the long-term safety of a treatment for people with advanced cancers known as HER2-expressing or HER2-mutated solid tumors. These are types of cancers that have specific changes in a protein called HER2, which can affect how the cancer grows. The treatment being studied is a medication called trastuzumab deruxtecan, also known by its code name DS-8201a. This medication is given as a solution through an infusion into the veins.

The purpose of the study is to provide continued access to this treatment for patients who are benefiting from it and to monitor its long-term safety. Participants in this study will continue to receive the medication as long as they are experiencing positive effects from it. The study will track any side effects or health changes that occur during this time.

Throughout the study, participants will receive regular infusions of the medication and will be monitored by healthcare professionals to ensure their safety. The study aims to gather information on any adverse events, which are unexpected health issues that might arise from the treatment. This information will help in understanding the long-term effects of the medication and ensuring it is safe for continued use in treating these types of cancers.

]]> Study of Pembrolizumab, Trastuzumab, and Drug Combination for Patients with HER2-Positive, Localized Esophagogastric Cancer https://clinicaltrials.eu/trial/study-of-pembrolizumab-trastuzumab-and-drug-combination-for-patients-with-her2-positive-localized-esophagogastric-cancer/ Wed, 29 Apr 2026 14:23:10 +0000 https://clinicaltrials.eu/trial/study-of-pembrolizumab-trastuzumab-and-drug-combination-for-patients-with-her2-positive-localized-esophagogastric-cancer/ This clinical trial is focused on studying a type of cancer called HER2-positive, localized esophagogastric adenocarcinoma. This is a cancer that affects the area where the esophagus meets the stomach and is characterized by an overexpression of a protein known as HER2. The study will explore the effectiveness of a combination of treatments, including pembrolizumab, trastuzumab, and a chemotherapy regimen known as FLOT. Pembrolizumab, also known by its code name MK-3475, is an immunotherapy drug that helps the immune system fight cancer. Trastuzumab, sometimes referred to by code names like PF-05280014, is a targeted therapy that specifically attacks HER2-positive cancer cells. FLOT is a combination of chemotherapy drugs used to treat this type of cancer.

The purpose of the study is to assess how well these treatments work together in preventing the cancer from returning and achieving a complete response, meaning no signs of cancer remain after treatment. Participants in the study will receive these treatments before and after surgery to remove the cancer. The study will monitor the participants’ health and response to the treatment over a period of time, with regular check-ups and assessments to ensure safety and effectiveness.

Throughout the study, participants will receive the treatments through intravenous infusions, which means the medication is delivered directly into the bloodstream through a vein. The study aims to provide valuable information on the potential benefits of combining these treatments for patients with HER2-positive esophagogastric adenocarcinoma, contributing to the development of more effective cancer therapies.

]]>